MediGene AG
Lochhamer Str. 11
Martinsried
82152
Germany
Tel: 49-89-85 65 29-00
Fax: 49-89-85 65 29-20
Website: http://www.medigene.de/
Email: medigene@medigene.de
285 articles about MediGene AG
-
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types
8/23/2023
Medigene AG announces the expansion of the IP license for its PD1-41BB and CD40L-CD28 costimulatory switch proteins, enabling their application to additional cell types and for use in Chimeric Antigen Receptor T cell therapies.
-
Medigene AG to present at the 8th CAR-TCR Summit in Boston
8/22/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 8th CAR-TCR Summit in Boston from August 29 to September 1, 2023.
-
Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update
8/17/2023
Planegg/Martinsried, August 17, 2023. Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial and operational results for the six months ended June 30, 2023.
-
Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023
8/10/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial and operational results for the six months ended June 30, 2023 on Thursday, August 17, 2023.
-
Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies
6/22/2023
Medigene AG presents an overview on elevated activity of T cell receptor engineered T cell therapies when combining Medigene´s PD1-41BB switch receptor with T cell receptors targeting different antigens at the Immuno-Oncology Summit Europe June 20-22, 2023 in London, UK.
-
Medigene to Present Data Highlighting the Enhanced Tumor Cell Killing Effects of Adding the PD1-41BB Switch Receptor to Multiple TCR-T Therapies at the Immuno-Oncology Summit Europe
6/14/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 7th annual Immuno-Oncology Summit Europe which will take place June 20-22, 2023 in London, UK.
-
Medigene to Host Virtual R&D Event on TCR-T Therapies for Solid Tumors
6/13/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will host an R&D Event to discuss the pipeline expansion and the evolution of its end-to-end platform on Tuesday, June 20, 2023, at 10:00 am ET.
-
Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs
6/1/2023
Medigene AG announces its pipeline expansion into neoantigens with KRAS as the first target in its MDG10xx program, a T cell receptor engineered T cell therapy being developed in combination with the company’s PD1-41BB switch receptor technology.
-
Medigene AG to participate at BIO International in Boston - May 30, 2023
5/30/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO International Convention, taking place June 5-8, 2023 in Boston, MA.
-
Medigene AG Expands Patent Portfolio for its End-to-End Platform
5/22/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor.
-
Medigene AG to present at upcoming May 2023 investor conferences
5/8/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the following upcoming investor conferences:
-
Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment
5/4/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents the webtool Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy, taking place May 3-5, 2023, in Mainz, Germany.
-
Medigene AG reports financial results and business update for Q1 2023
5/3/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial results for the first quarter of 2023.
-
Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors
5/2/2023
Medigene AG reports it has partnered with Helmholtz Munich to acquire the exclusive, worldwide rights to the CD40L-CD28 costimulatory switch receptor adding to the portfolio of technologies within Medigene’s end-to-end platform.
-
Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
4/27/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20th Association for Cancer Immunotherapy annual meeting being held on May 3-5, 2023, in Mainz.
-
Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers
4/24/2023
Medigene AG reports final Phase I dose escalation results from first-in-human Study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell therapy for high-risk myeloid and lymphoid neoplasms.
-
New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015)
4/18/2023
Medigene AG today presents preclinical data on MDG1015, a T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1) combined with the Company’s PD1-41BB switch receptor technology at the AACR Annual Meeting 2023, taking place April 14-19, 2023, in Orlando, Florida.
-
Medigene AG to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting
4/11/2023
Medigene AG will present a poster at the European Society for Blood and Marrow Transplantation (EBMT) 2023 annual meeting being held on April 23-26, 2023 in Paris.
-
Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development
4/4/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr. Dolores Schendel, Medigene‘s Chief Scientific Officer, has been invited to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston on April 04, 2023.
-
Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs
4/3/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, and the National Cancer Institute (NCI) will collaborate to evaluate the potential of Medigene’s proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors.